当前位置：易推广 > 上海陶术生物科技有限公司 > 产品展示
企业档案
会员类型：会员
已获得易推广信誉 等级评定
(0 -40)基础信誉积累，可浏览访问
(41-90)良好信誉积累，可接洽商谈
(91+ )优质信誉积累，可持续信赖
易推广会员：5年
工商认证 【已认证】
最后认证时间：
注册号： 【已认证】
法人代表： 【已认证】
企业类型：生产商 【已认证】
注册资金：人民币万 【已认证】
产品数：86104
参观次数：3211463
自主品牌
已选条件
-
T6561Laquinimodinhibit,multiple sclerosis,relapsing remitting,carboxamide,Nuclear factor-kappaB,Apoptosis
Laquinimod is an effective immunomodulator, which is currently under development in phase III trials for the treatment of multiple sclerosis as an oral therapy.
价 格：￥电议型 号：T6561产 地：中国大陆
-
T6561LaquinimodLaquinimod,ABR-215062,LAQ
Laquinimod is an effective immunomodulator, which is currently under development in phase III trials for the treatment of multiple sclerosis as an oral therapy.
价 格：￥电议型 号：T6561产 地：美洲
-
T6561Laquinimod；拉喹莫德LAQ|||ABR-215062；LAQ|||ABR-215062|||拉喹莫德
Laquinimod (LAQ) is an effective immunomodulator, which is currently under development in phase III trials for the treatment of multiple sclerosis as an oral therapy.
价 格：￥电议型 号：T6561产 地：中国大陆
-
T61607Laquinimod sodium；化合物 Laquinimod sodiumLaquinimod sodium
Laquinimod (ABR-215062) sodium is a carboxamide derivative administered orally that serves as a powerful immunomodulator, designed to prevent inflammation and neurodegeneration within the central nervous system. This compound effectively diminishes the activation of astrocytic NF-κB, offering protection against Cuprizone-induced demyelination. It shows promise for the treatment of both relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS), in additi
价 格：￥电议型 号：T61607产 地：中国大陆
